Alyn H Morice, ATS 2022: Phase 2 Trial of BLU-5937 for Refractory Chronic Cough
touchRESPIRATORY were delighted to speak with Prof. Alyn H Morice (Hull York Medical School, University of Hull, Yorkshire, UK) to discuss the phase 2 trial, investigating BLU-5937 a selective P2x3 antagonist for the treatment of refractory chronic cough.
The abstract ‘Responders Analyses in Objective 24H Cough Frequency in Soothe, A Phase 2b Trial of a Selective P2x3 Antagonist in Refractory Chronic Cough.‘ (Abstract number: P511) was presented at ATS 2022, 13-18 May 2022.
- Could you tell us a little about the clinical burden of refractory chronic cough (RCC) and the unmet needs in its treatment? (0:31)
- What is BLU-5937 and what is the rationale for its use in the treatment of RCC? (1:45)
- What were the aims, design and eligibility criteria of the SOOTHE study? (3:09)
- What were the findings of the responder analysis? (3:48)
- What factors predicted response to BLU-5937? (4:14)
Disclosures: Alyn H Morice discloses consulting for Bellus and serving on advisory boards for Bellus.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ATS meeting 2022.
Share this Video
Related Videos In Chronic Cough
Alan Kaplan: The IPCRG Sentinel Network and Respiratory Q&A
We were delighted to meet with Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) to discuss the international IPCRG Sentinel Network which represents each continent and includes over 100 primary care clinicians. The IPCRG is providing answers based on published peer reviewed evidence to COVID and respiratory questions from the Sentinel Network. Questions Could […]
James Wingfield Digby, ERS 2022: Hypotonic Saline in the Diagnosis of Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population; however chronic cough is often unrecognized, underdiagnosed and there remain many unmet needs in its treatment. It was a pleasure to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around his study […]
James Wingfield Digby, ERS 2022: Low-dose Opiates for Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population. touchRESPIRATORY were delighted to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around the aims and design of the real world study investigating low-dose opiates in the treatment of chronic cough and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!